QUEST DIAGNOSTICS INC News
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
see moreQUEST DIAGNOSTICS INC Market News
1d
Quest Diagnostics Surges: MRD Test, Dividend Boost
- Quest Diagnostics (DGX) posted strong Q4 results, introduced a blood-based MRD test for multiple myeloma, and announced a meaningful dividend increase plus a $1 billion buyback authorization. These concrete developments strengthen DGX’s growth and shareholder-return thesis, while Medicare reimbursement pressure and ongoing IT modernization remain key operational factors to monitor.
8d
DGX: Beat, Dividend Hike, Medicare Cut Risk Ahead.
Quest Diagnostics (DGX) reported a Q4 beat, raised 2026 guidance, boosted its dividend and expanded buybacks—sparking a notable share gain—while looming Medicare reimbursement cuts for hundreds of lab tests create a tangible near-term policy risk.
15d
Quest Diagnostics Jumps After Q4 Beat, Big Buyback
Quest Diagnostics (DGX) surged after reporting a stronger-than-expected Q4 with revenue of $2.81B and adjusted EPS of $2.42, while announcing a 7.5% dividend increase and $1B additional share buyback authorization. Analysts raised price targets and the stock briefly hit a 52-week high, signaling investor confidence tied to durable diagnostic demand and robust capital returns.
22d
DGX Ahead of Earnings: Corewell JV Boosts Outlook!
Quest Diagnostics (DGX) rallied last week as investors weighed an upcoming Q4 & full-year 2025 earnings release and the completed Corewell Health joint venture. Recent price gains, volume upticks, and corporate recognition position DGX ahead of its Feb. 10, 2026 results; near-term direction will hinge on revenue trends, diagnostic volumes, and guidance.